While it sends some signals about the priorities of new FDA Commissioner Dr Martin Makary, the actual impact of the directive ...

GSK's Blenrep (belantamab mafodotin) has officially been approved by the UK's Medicines and Healthcare products Regulatory ...

An international agreement on pandemic preparedness is finally complete after three years of negotiation. The World Health ...

Merida Biosciences has emerged from Third Rock Ventures with $121 million in first-round financing for a pipeline of drugs ...

This new approach to lab space is emblematic of a broader trend in real estate: the conversion of under-utilised office space ...

Pursue advocacy efforts We’ve seen critical legal decisions over the last five years either accelerate or stymie the United States biosimilar market. In the 2017 Amgen v. Sandoz case, the ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbosacral radiculopathy (LSR), a form of neuropathic back pain, ahead of an FDA ...

The EMA's human medicines committee has said it does not recommend approval of Eli Lilly's anti-amyloid Alzheimer's disease treatment Kisunla, saying its modest benefits don't outweigh its risks.

CSL Behring has added another major European market to the list of those providing reimbursement coverage of its haemophilia B gene therapy Hemgenix, after agreeing an access deal in Germany.

Randall Bateman, MD, Charles F and Joanne Knight Distinguished Professor of Neurology at WashU Medicine. A study of Roche's anti-amyloid drug gantenerumab has suggested that early treatment to ...

Novartis has a third FDA-approved indication for its oral therapy for complement-mediated diseases – Fabhalta – after getting a green light in ultra-rare kidney disease C3 glomerulopathy (C3G).